AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Researchers in Japan report positive results in their study of dendritic cell-based immunotherapy of pancreatic cancer in a hamster model.
"Because the prognosis of patients with pancreatic cancer is very poor, development of a novel approach for treatment of this disease is vital. In the present study, we investigated the effect of dendritic cell (DC)-based immunotherapy against established syngeneic hamster pancreatic cancer named HPD1NR," wrote Y. Akiyama and colleagues, National Cancer Center, Research Institute, Tokyo.
"Hamster enriched DCs were prepared from bone marrow (BM) by a culture for 7 days in the presence of mouse GM-CSF [granulocyte-macrophage colony-stimulating factor] and mouse IL-4 [interleukin-4], and characterized by the expression of specific DC markers (DEC205, DC-SIGN) mRNA using in situ hybridization (ISH). DCs pulsed with tumor lysate and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) or DCs alone were injected s.c. weekly into HPDINR-bearing hamsters three times," the researchers explained.
Akiyama and colleagues reported that ...
Source: HighBeam Research, Antitumor effects induced by dendritic cell-based immunotherapy in...